BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Black Diamond Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.81+0.09 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $103.83M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Black Diamond Therapeutics has not reported a dividend
No dividend per share appears in Black Diamond Therapeutics's annual filings since fiscal 2017.